Company Description
Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of inherited retinal diseases.
The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for the treatment of presbyopia and dim light or night vision disturbances; APX3330, a small-molecule inhibitor of Ref-1 that has completed Phase II clinical trial for the treatment of diabetic retinopathy; andOPGx-LCA5, an early-onset retinal degeneration which is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; OPGx-BEST1, developed for bestrophin-1 (BEST1)-related inherited retinal diseases or bestrophinopathies.
Its other pre-clinical IRD pipeline, including OPGx-RHO, OPGx-RDH12, OPGx-MERTK, OPGx-NMNAT1, and OPGx-GNGB.
The company was formerly known as Ocuphire Pharma, Inc. Opus Genetics, Inc. was founded in 2018 and is headquartered in Farmington Hills, Michigan.
| Country | United States |
| Founded | 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 18 |
| CEO | George Magrath |
Contact Details
Address: 8 Davis Drive, Suite 220 Durham, North Carolina 27709 United States | |
| Phone | 984 884 6030 |
| Website | ir.opusgtx.com |
Stock Details
| Ticker Symbol | IRD |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001228627 |
| ISIN Number | US67577R1023 |
| Employer ID | 11-3516358 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| George Magrath M.B.A., M.D., M.S. | Chief Executive Officer and Director |
| Dr. Benjamin R. Yerxa Ph.D. | President and Director |
| Nirav Suresh Jhaveri C.F.A. | Chief Financial Officer |
| Dr. Ashwath Jayagopal Ph.D. | Chief Scientific and Development Officer |
| Joseph K. Schachle MBA | Chief Operating Officer |
| Bernhard Hoffmann M.B.A. | Senior Vice President of Corporate Development and Secretary |
| Amy Zaremba Rabourn C.P.A., MAcc | Senior Vice President of Finance |
| Bindu Manne | Head of Market Development and Commercialization |
| Erik Sims | Director and Corporate Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 14, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 11, 2025 | PX14A6G | Notice of exempt solicitation submitted by non-management |
| Apr 11, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 10, 2025 | EFFECT | Notice of Effectiveness |
| Apr 10, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 9, 2025 | DFAN14A | Filing |
| Apr 8, 2025 | S-3/A | [Amend] Registration statement under Securities Act of 1933 |
| Apr 7, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 4, 2025 | 8-K | Current Report |
| Apr 4, 2025 | 424B5 | Filing |